Nanoform, which recently announced construction of a new GMP manufacturing facility in Helsinki, has announced the appointment of Niklas Sandler as Chief Technology Officer. Sandler was most recently Vice Rector responsible for Research Affairs and Professor of Pharmaceutical Technology at Åbo Akademi University, and he is Chairman of the Board of the Finnish Pharmaceutical Society. His prior experience includes several scientist positions at AstraZeneca.
The company cited the appointments of Sandler and of Gonçalo Rebelo de Andrade as Chief of Business Operations, along with the announcement of the new facility, as steps taken to “ensure that Nanoform delivers exceptional solutions to address its partners’ complex product development challenges.”
Sandler said, “I am excited to be joining Nanoform’s dynamic environment and a team that is passionate about transforming the pharmaceutical industry. My career has focused on enhancing the commercial application of research, and Nanoform’s use of cutting-edge nanonization technology exemplifies how innovations are transforming the sector.”
Nanoform CEO Edward Hæggström commented, “I am delighted to welcome Niklas Sandler to Nanoform. His exceptional experience in pharmaceutical technology and product development will be a huge asset to the company and allow us to set ambitious goals to enhance our commercial offering.”
Read the Nanoform press release.
